A single-dose study of HP-3180

Status

Recruiting

Phases

Phase 1

Study type

Interventional

Source

JPRN

Registry ID

JPRN-jRCT2031250597

Enrollment

Registered

2025-12-24

Start date

2026-01-06

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Healthy adult

Interventions

Step1: a single dose of HP-3180 Dose 1 will be administered. a single dose of control drug will be administered. Step2: a single dose of HP-3180 Dose 2 will be administered. Step3: a single dose of HP

Eligibility

Sex/Gender

Female

Inclusion criteria

Inclusion criteria: - Healthy Japanese adult females aged >=18 and <=35 years - Subjects weighting 40 kg or more

Exclusion criteria

Exclusion criteria: - Subjects who received any drug within 1 week prior to administration of the investigational product - Subjects who took any drug considered to affect drug metabolism within 4 weeks prior to administration of the investigational product

Design outcomes

Primary

Measure	Time frame
Pharmacokinetics, Safety	—

Contacts

Public ContactContact for Clinical Trial Information Clinical Development Department

Hisamitsu Pharmaceutical Co., Inc.

shikenjoho@hisamitsu.co.jp+81-3-5293-1734

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026